| Dr Pamela M Simmons, DO | |
|
100 Womans Way, Baton Rouge, LA 70817-5100 | |
| (225) 924-8338 | |
| Not Available |
| Full Name | Dr Pamela M Simmons |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 12 Years |
| Location | 100 Womans Way, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982950648 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VM0101X | Obstetrics & Gynecology - Maternal & Fetal Medicine | 320801 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Womans Hospital | Baton rouge, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lsuhn Billing Llc | 0446337802 | 194 |
| Woman's Maternal Fetal Medicine | 3971408063 | 4 |
| Ochsner Clinic Llc | 8224933619 | 2403 |
News Archive
A team of University of Pennsylvania researchers has developed a computer model that will aid in the design of nanocarriers, microscopic structures used to guide drugs to their targets in the body.
MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).
The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.
EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.
› Verified 4 days ago
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
A team of University of Pennsylvania researchers has developed a computer model that will aid in the design of nanocarriers, microscopic structures used to guide drugs to their targets in the body.
MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).
The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.
EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.
› Verified 4 days ago
| Entity Name | Woman's Maternal Fetal Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396780193 PECOS PAC ID: 3971408063 Enrollment ID: O20031203000051 |
News Archive
A team of University of Pennsylvania researchers has developed a computer model that will aid in the design of nanocarriers, microscopic structures used to guide drugs to their targets in the body.
MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).
The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.
EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.
› Verified 4 days ago
| Entity Name | St Francis Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437149168 PECOS PAC ID: 7810892718 Enrollment ID: O20031204000183 |
News Archive
A team of University of Pennsylvania researchers has developed a computer model that will aid in the design of nanocarriers, microscopic structures used to guide drugs to their targets in the body.
MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).
The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.
EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.
› Verified 4 days ago
| Entity Name | Thibodaux Regional Network Development Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285658310 PECOS PAC ID: 8224011754 Enrollment ID: O20040608000132 |
News Archive
A team of University of Pennsylvania researchers has developed a computer model that will aid in the design of nanocarriers, microscopic structures used to guide drugs to their targets in the body.
MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).
The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.
EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.
› Verified 4 days ago
| Entity Name | Lsuhn Billing Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992975775 PECOS PAC ID: 0446337802 Enrollment ID: O20080409000372 |
News Archive
A team of University of Pennsylvania researchers has developed a computer model that will aid in the design of nanocarriers, microscopic structures used to guide drugs to their targets in the body.
MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).
The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.
EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.
› Verified 4 days ago
| Entity Name | North Oaks Medical Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962709501 PECOS PAC ID: 2466629522 Enrollment ID: O20120125000648 |
News Archive
A team of University of Pennsylvania researchers has developed a computer model that will aid in the design of nanocarriers, microscopic structures used to guide drugs to their targets in the body.
MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).
The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.
EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.
› Verified 4 days ago
| Entity Name | North Oaks Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427035211 PECOS PAC ID: 9133378870 Enrollment ID: O20121012000490 |
News Archive
A team of University of Pennsylvania researchers has developed a computer model that will aid in the design of nanocarriers, microscopic structures used to guide drugs to their targets in the body.
MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).
The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.
EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Pamela M Simmons, DO 100 Womans Way, Baton Rouge, LA 70817-5100 Ph: (501) 410-7437 | Dr Pamela M Simmons, DO 100 Womans Way, Baton Rouge, LA 70817-5100 Ph: (225) 924-8338 |
News Archive
A team of University of Pennsylvania researchers has developed a computer model that will aid in the design of nanocarriers, microscopic structures used to guide drugs to their targets in the body.
MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).
The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.
EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.
› Verified 4 days ago
Sarah Buzhardt, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 500 Rue De La Vie, Suite 414, Baton Rouge, LA 70817 Phone: 225-215-7960 Fax: 225-922-3382 | |
Jeffrey L Janies, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 500 Rue De La Vie St Ste 305, Baton Rouge, LA 70817 Phone: 225-927-5480 Fax: 225-925-0896 | |
William D Binder, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 500 Rue De La Vie St, Suite 100, Baton Rouge, LA 70817 Phone: 225-201-2000 Fax: 225-201-2110 | |
Dr. James Gordon Gengelbach, DO Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 5145 Bluebonnet Blvd, Baton Rouge, LA 70809 Phone: 225-408-1422 Fax: 225-408-1462 | |
Dr. Carol M Patin, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 8595 Picardy Ave, Suite 230, Baton Rouge, LA 70809 Phone: 225-763-4990 Fax: 225-763-4987 | |
Dr. Kristin Bassett Chapman, MD Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 500 Rue De La Vie, Suite 210, Baton Rouge, LA 70817 Phone: 225-928-5951 Fax: 225-928-5535 | |
Morgan Moore Bankston, M.D. Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 500 Rue De La Vie St Ste 100, Baton Rouge, LA 70817 Phone: 225-201-2000 |